Kaleido Biosciences, Inc. (KLDO)
| Market Cap | 4.26K -99.0% |
| Revenue (ttm) | 1.10M +13.2% |
| Net Income | -90.29M |
| EPS | -2.16 |
| Shares Out | 42.62M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,679 |
| Open | 0.0001 |
| Previous Close | n/a |
| Day's Range | 0.0001 - 0.0001 |
| 52-Week Range | n/a |
| Beta | 40.03 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About Kaleido Biosciences
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of ulcerative colitis, psoriasis, atopic immune disease, chronic obstructive pulmonary disease pathogens, and immuno-oncology. The company has collaboration agreements with Institute Gustave Rous... [Read more]
News
Kaleido Biosciences to Present Updated Data of KB295 In Ulcerative Colitis at the 2022 Crohn's and Colitis Congress
LEXINGTON, Mass., Jan. 21, 2022 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage biotech company with a differentiated, small-molecule approach to treating inflammatory c...
Kaleido Biosciences Announces Expansion of Collaboration with Janssen to Explore Potential of Microbiome Metabolic Therapies (MMT™) to Prevent Childhood-Onset of Atopic, Immune and Metabolic Conditions
LEXINGTON, Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage biotech company with a differentiated, small-molecule approach to treating inflammatory c...
Kaleido Biosciences to Appoint Dr. Alison Long as Chief Medical Officer
LEXINGTON, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage biotech company with a differentiated, small-molecule approach to treating inflammatory c...
Kaleido Biosciences Reports Third Quarter 2021 Financial Results
--Achieved primary objective of safety and tolerability in clinical study evaluating KB295 in mild-to-moderate ulcerative colitis; meaningful reduction observed in key biomarkers correlated with disea...
Kaleido Biosciences to Participate in the Jefferies Virtual Next Generation IBD Therapeutics Summit
LEXINGTON, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage biotech company with a differentiated, small-molecule approach to treating inflammatory c...
Kaleido Biosciences to Host Virtual R&D Presentation to Discuss Clinical Data and Pipeline Advancement on October 5, 2021
Latest data and clinical development plans for KB295 in ulcerative colitis (UC) to be presented
Kaleido Biosciences to Participate in the Morgan Stanley 19th Annual Virtual Global Healthcare Conference
LEXINGTON, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the mic...
Kaleido Biosciences Reports Second Quarter 2021 Financial Results
--On track to report topline data from a clinical study of KB295 in patients with mild-to-moderate ulcerative colitis by end of third quarter-- --Kaleido and the COPD Foundation to collaborate on the ...
Kaleido Biosciences and the COPD Foundation Announce a Strategic Collaboration to Advance KB109 into Phase 2 Clinical Trial
On track to initiate Phase 2 trial in the first quarter of 2022 On track to initiate Phase 2 trial in the first quarter of 2022
Kaleido Biosciences Announces New Chairperson Appointment to its Board of Directors
Current Director Theo Melas-Kyriazi appointed Chairperson of the Board of Directors Current Director Theo Melas-Kyriazi appointed Chairperson of the Board of Directors
Kaleido Biosciences to Participate in the 41st Annual Canaccord Genuity Growth Conference
LEXINGTON, Mass., Aug. 06, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the micr...
Kaleido Biosciences to Participate in the JMP Securities Life Sciences Conference
LEXINGTON, Mass., June 10, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the micr...
Kaleido Biosciences Reports First Quarter 2021 Financial Results
--Positive results in patients with mild-to-moderate COVID-19 demonstrate KB109's potential to reduce healthcare utilization and recovery time; initiating IND application to support further developmen...
Kaleido Biosciences Announces Collaboration with Robert Jenq, M.D., to Explore Potential of its Microbiome Metabolic Therapies (MMT™) in Preventing Febrile Neutropenia
LEXINGTON, Mass., April 20, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a small molecule driven approach to targeting the microbiome to ...
Kaleido Biosciences to Participate in Jefferies Microbiome-Based Therapeutics Summit
LEXINGTON, Ma., April 15, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the micro...
Biotech company Kaleido develops oral therapy for COVID-19
Dan Menichella, Kaleido CEO, joins Yahoo Finance's Anjalee Khemlani, Alexis Christoforous and Kristin Myers to discuss the utilization of oral therapeutic KB109 for COVID-19 and emerging variants.
Kaleido Biosciences Reports Positive Results from Non-IND Study Demonstrating a Reduction in COVID-19 Related Healthcare Utilization and Recovery Time in Patients with Mild-to-Moderate COVID-19 and One or More Comorbidity
KB109 demonstrated favorable safety and tolerability profile
Kaleido Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results
Topline data from two ongoing COVID-19 studies with KB109 expected in Q1 2021
Kaleido Biosciences to Present at Chardan's 3rd Annual Microbiome Medicines Summit
LEXINGTON, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the mic...
Cellarity Raises $123 Million in Series B Funding to Pioneer a New Approach to Drug Discovery, Treating Disease at the Level of the Cell as Opposed to a Single Molecular Target
CAMBRIDGE, Mass., Feb. 25, 2021 /PRNewswire/ -- Cellarity, a life sciences company founded by Flagship Pioneering to develop a new method of drug discovery targeting the cell, announced today that it ...
Kaleido Biosciences Announces the Exercise of the Underwriters' Option to Purchase Additional Shares of Common Stock
LEXINGTON, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the micr...
Kaleido Biosciences Announces Pricing of Public Offering of Common Stock
LEXINGTON, Mass., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the micr...
Kaleido Biosciences Announces Proposed Public Offering of Common Stock
LEXINGTON, Mass., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the micr...
Kaleido Biosciences to Present at the Keystone Symposium “Harnessing the Microbiome for Disease Prevention and Therapy” Conference
LEXINGTON, Mass., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), today announced Johan van Hylckama Vlieg, Ph.D., Chief Scientific Officer, will present at the Keystone Sy...
Kaleido Biosciences Announces Positive Interim Results of Controlled Study of KB109 in Patients with Mild-to-Moderate COVID-19
Preliminary analysis (n=176) demonstrates favorable safety and tolerability; data provide a strong signal of clinical benefit for subjects reporting one or more comorbidities